Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction
ER Cosentino, D Degli Esposti, R Miceli… - Current Medical …, 2019 - Taylor & Francis
Objective: We evaluated the clinical efficacy of sacubitril/valsartan in a group of ambulatory
patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF …
patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF …
Impact of Sacubitril–Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
P Pericas, C Mas-Lladó, MF Ramis-Barceló… - High Blood Pressure & …, 2021 - Springer
Abstract Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …
Impact of sacubitril/valsartan on clinical and echocardiographic parameters in heart failure patients with reduced ejection fraction: data from a real life 2-year follow-up …
G Armentaro, G D'Arrigo, M Magurno… - Frontiers in …, 2021 - frontiersin.org
Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
MV Polito, A Silverio, A Rispoli, G Vitulano, FD Auria… - Scientific Reports, 2020 - nature.com
The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …
laboratory and echocardiographic parameters and outcomes in a real-world population with …
[HTML][HTML] Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
M Landolfo, F Piani, D Degli Esposti, E Cosentino… - IJC Heart & …, 2020 - Elsevier
Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study
Background Sacubitril/valsartan improves outcome in patients with heart failure (HF) with
reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about …
reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about …
The effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure with reduced ejection fraction: the “ …
G Romano, G Vitale, L Ajello, V Agnese… - Journal of clinical …, 2019 - mdpi.com
Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the
risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on …
risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on …
Comparison of the effect of sacubitril/valsartan on left ventricular systolic function in patients with non-ischaemic and ischaemic cardiomyopathy
A Ioannou, S Metaxa, S Simon, AKJ Mandal… - … Drugs and Therapy, 2020 - Springer
Purpose Sacubitril/valsartan has been demonstrated to improve prognosis and outcomes in
heart failure with reduced ejection fraction (HFrEF) patients. We sought to compare the …
heart failure with reduced ejection fraction (HFrEF) patients. We sought to compare the …
[HTML][HTML] Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients
A Almufleh, J Marbach, S Chih, E Stadnick… - American journal of …, 2017 - ncbi.nlm.nih.gov
Background: Sacubitril/Valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …
hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The …
Evaluating sacubitril/valsartan dose dependence on clinical outcomes in patients with heart failure with reduced ejection fraction
K Kido, C Bianco, M Caccamo… - Annals of …, 2021 - journals.sagepub.com
Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …